Research Analysts Issue Forecasts for ResMed Inc.’s Q3 2025 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Research analysts at William Blair boosted their Q3 2025 earnings estimates for shares of ResMed in a report released on Friday, August 2nd. William Blair analyst M. Kaczor now anticipates that the medical equipment provider will post earnings of $2.21 per share for the quarter, up from their prior estimate of $2.10. The consensus estimate for ResMed’s current full-year earnings is $8.79 per share. William Blair also issued estimates for ResMed’s Q4 2025 earnings at $2.32 EPS.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. ResMed had a net margin of 21.79% and a return on equity of 25.58%. ResMed’s revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.60 earnings per share.

RMD has been the topic of a number of other reports. Royal Bank of Canada upped their target price on shares of ResMed from $204.00 to $206.00 and gave the stock a “sector perform” rating in a research report on Friday, August 2nd. Oppenheimer cut ResMed from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 25th. Needham & Company LLC reiterated a “buy” rating and set a $236.00 price objective on shares of ResMed in a research note on Friday, August 2nd. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, KeyCorp upped their price target on shares of ResMed from $238.00 to $251.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $204.70.

ResMed Trading Up 1.5 %

NYSE RMD opened at $218.95 on Monday. The firm has a market capitalization of $32.17 billion, a PE ratio of 33.63, a P/E/G ratio of 1.93 and a beta of 0.66. The stock’s 50 day moving average is $203.94 and its 200 day moving average is $196.95. ResMed has a twelve month low of $132.24 and a twelve month high of $225.68. The company has a quick ratio of 1.97, a current ratio of 3.04 and a debt-to-equity ratio of 0.22.

ResMed Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.97%. This is a boost from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date is Thursday, August 15th. ResMed’s payout ratio is presently 29.49%.

Insider Activity at ResMed

In other news, CEO Michael J. Farrell sold 14,683 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $211.66, for a total value of $3,107,803.78. Following the transaction, the chief executive officer now directly owns 440,799 shares in the company, valued at approximately $93,299,516.34. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Justin Leong sold 48,000 shares of ResMed stock in a transaction on Monday, August 5th. The shares were sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the transaction, the insider now owns 18,741 shares in the company, valued at approximately $4,068,108.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 14,683 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $211.66, for a total value of $3,107,803.78. Following the completion of the sale, the chief executive officer now owns 440,799 shares of the company’s stock, valued at $93,299,516.34. The disclosure for this sale can be found here. Insiders have sold a total of 79,726 shares of company stock worth $16,843,287 over the last quarter. Company insiders own 1.21% of the company’s stock.

Institutional Trading of ResMed

Several hedge funds have recently bought and sold shares of RMD. Atlantic Edge Private Wealth Management LLC purchased a new position in shares of ResMed during the 4th quarter valued at about $27,000. Hall Laurie J Trustee purchased a new position in ResMed during the first quarter valued at approximately $32,000. OFI Invest Asset Management bought a new position in shares of ResMed in the second quarter worth approximately $32,000. BOK Financial Private Wealth Inc. purchased a new stake in shares of ResMed in the first quarter worth $35,000. Finally, Versant Capital Management Inc raised its position in shares of ResMed by 196.7% during the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 120 shares during the period. Institutional investors own 54.98% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.